Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1921 + adebrelimab + SHR-8068 ± carboplatin in advanced non-small cell lung cancer
CTR20241898Phase 2Terminated
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Jun 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tizetatug rezetecan in non-small cell lung cancer (NSCLC), sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Jun 2024; status: terminated.
02
Drugs
tizetatug rezetecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20241898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241898.